Loading…
Loading…
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for TRNLY and 80,000+ other tickers.
See exactly how TRNLY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for TRNLY and 80,000+ other tickers.
The Trendlines Group Ltd. operates as an enterprise dedicated to bringing innovations to market, simultaneously functioning as a private equity and venture capital firm. Its investment strategy comprehensively covers all company stages, from initial incubation and seed funding to early and late-stage venture capital rounds. The firm allocates capital across a broad spectrum of industries. These include food, environmental (clean) technologies, agricultural technology, and a significant focus on life sciences, particularly medical devices, biotechnology, and pharmaceuticals. They also seek…
Enables natural orifice extraction of tissue without surgical incision SINGAPORE, July 20, 2026 /PRNewswire/ -- NICE Surgical Solutions Pte Ltd ("NICE Surgical"), a clinical-stage medical device company pioneering full intracorporeal anastomosis surgical instruments, has been granted U.S. Patent No. 12,661,097 B2, for its extracting device used in conjunction with its novel purse-string stapler, generally eliminating the need for surgical incisions in colorectal surgery.
Enables intracorporeal purse-sting suturing, stapling, and resection in a single firing SINGAPORE, July 1, 2026 /PRNewswire/ -- NICE Surgical Solutions Pte Ltd ("NICE Surgical"), a clinical-stage medical device company pioneering full intracorporeal anastomosis surgical instruments has been officially granted the U.S. Patent No. 12,653,527 B2, for its purse-string stapler.
Pfizer Inc (NYSE:PFE) stock is down 1.1% to trade at $26.03 at last check.
POC included in vivo insect validation of de novo designed proteins NES TZIONA, Israel, March 10, 2026 /PRNewswire/ -- IBI Ag Ltd. ('IBI Ag'), a leader in sustainable agricultural solutions, has today announced the successful completion of its proof of concept (POC) for the AI-driven platform for de novo design of novel bioinsecticide proteins.
Last week looked like a strong start for a Santa Claus rally